Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Q2 Results in Detail

Research and development (R&D) expenses were $56.1 million in the reported quarter, up around 31.2% year over year. The rise was mainly due to increased clinical and manufacturing activities associated with ongoing clinical studies.  

General and administrative expenses were $10.7 million, down nearly 15.6% year over year, primarily due to lower non-cash stock-based compensation expenses.

As of June 30, 2026, Kodiak had cash, cash equivalents and marketable securities worth $125.9 million compared with $169.5 million as of March 31, 2026. The company expects its cash position to support ongoing operations into 2027.

Year to date, shares of Kodiak have risen 42.9% compared with the industry’s 6.7% growth.

Image Source: Zacks Investment Research

KOD's Key Pipeline Updates

Backed by strong safety, efficacy and durability data from the GLOW2 study in March, Zenkuda Kodiak’s lead candidate, has achieved a multi-indication, approval-ready profile, leading Kodiak to accelerate its regulatory submission timeline.

Zenkuda is advancing toward biologics license application submission, with the company focused on regulatory, manufacturing and related preparations.

KOD’s second clinical candidate, KSI-501, is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases.

The company is studying Zenkuda as a second investigational arm in the phase III DAYBREAK study for the treatment of wet age-related macular degeneration (wet AMD), with KSI-501 being the first investigational arm. KOD has completed enrollment in the study. Top-line data from both arms of the DAYBREAK study are anticipated in September 2026.

Earlier this month, Kodiak initiated a global late-stage ALTO study evaluating the safety and efficacy of intravitreal KSI-501 versus Eylea (aflibercept) in patients with diabetic macular edema (DME). Patient enrollment is ongoing.

Previously, Kodiak had completed an early-stage study (APEX) evaluating its third investigational candidate, KSI-101, for macular edema. The candidate is a novel, potent, high-strength bispecific protein targeting IL-6 and VEGF.

Following the candidate’s success in the early-stage study, KOD is investigating two dose levels (5 mg and 10 mg) of KSI-101 for macular edema secondary to inflammation in two separate pivotal phase III studies (PEAK and PINNACLE).

Kodiak completed enrollment in the first cohort of the PEAK study earlier this month, with top-line data expected in December 2026. Enrollment in the second cohort of the PEAK and PINNACLE studies is expected to finish in the fourth quarter of  2026, with top-line data anticipated in the second quarter of 2027.

KOD's Zacks Rank & Stocks to Consider

Kodiak currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals AMRX, currently sporting a Zacks Rank #1 (Strong Buy), while AC Immune ACIU and Altimmune ALT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 40.2% year to date.

Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 18.2% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Over the past 60 days, estimates for Altimmune’s 2026 loss per share have narrowed from 69 cents to 64 cents. Over the same period, loss estimates for 2027 have improved from 73 cents to 64 cents. ALT shares have declined 16.9% year to date.

Altimmune’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 16.90%.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research